These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 35861904)

  • 1. Letter to the Editor: Lazzaro responds to Rodríguez‑Sánchez et al.
    Lazzaro C
    Eur J Health Econ; 2023 Jun; 24(4):661-662. PubMed ID: 35861904
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to letter by Hadigal et al. regarding the cost-effectiveness of high dose quadrivalent vaccine in three European countries.
    Alvarez FP; Bricout H; Marques C; Soininen A; Sainio T; Petit C; de Courville C; Chevalierf P
    J Med Econ; 2023; 26(1):1167-1168. PubMed ID: 37455595
    [No Abstract]   [Full Text] [Related]  

  • 3. Modeling the cost-effectiveness of prolonged-release fampridine for the treatment of walking impairment in patients with multiple sclerosis in Sweden.
    Acosta C; Gianinazzi M; Dort T; Armstrong N; Ryder S; Lundqvist T; Ekelund M; Lycke J
    J Med Econ; 2021; 24(1):770-780. PubMed ID: 33966549
    [No Abstract]   [Full Text] [Related]  

  • 4. Letter to the editor regarding Gholamzad et al., "A comprehensive review on the treatment approaches of multiple sclerosis: currently and in the future".
    Faissner S
    Inflamm Res; 2020 Feb; 69(2):153. PubMed ID: 31927617
    [No Abstract]   [Full Text] [Related]  

  • 5. Response to Letter to the Editor Regarding the Article Entitled "Treatment Effects for Dysphagia in Adults with Multiple Sclerosis: A Systematic Review".
    Bogaardt H; Alali D; Ballard K
    Dysphagia; 2021 Dec; 36(6):1116-1117. PubMed ID: 33245423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Letter to the editor re: Worsening disability status in multiple sclerosis predicts urologic complications. Int Urol Nephrol. May; 52(5):859-863. doi: 10.1007/s11255-020-02381-6. Epub 2020 Jan 25 by Abello et al.
    Floyd MS; Khadr RN; Young CA
    Int Urol Nephrol; 2020 Dec; 52(12):2307-2308. PubMed ID: 32588318
    [No Abstract]   [Full Text] [Related]  

  • 7. Response to the letter to the Editor for the manuscript 'Focal muscle vibration, an effective rehabilitative approach in severe gait impairment due to multiple sclerosis' by Nardone et al.
    Camerota F; Suppa A; De Fino C; Celletti C; Nociti V
    J Neurol Sci; 2017 Apr; 375():488. PubMed ID: 28202200
    [No Abstract]   [Full Text] [Related]  

  • 8. Standardized Sensitivity Analysis in BCA: An Education Case Study.
    Pradhan E; Jamison DT
    J Benefit Cost Anal; 2019; 10(Suppl 1):206-223. PubMed ID: 32983834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re: Letter to the editor by Cameron et al.
    Jacobs JV; Kasser SL
    Gait Posture; 2014; 39(1):670. PubMed ID: 24184136
    [No Abstract]   [Full Text] [Related]  

  • 10. Lazzaro responds to Pouwels et al.
    Lazzaro C
    Breast Cancer Res Treat; 2021 Nov; 190(1):1. PubMed ID: 34355299
    [No Abstract]   [Full Text] [Related]  

  • 11. Letter to the editor re: the effect of pelvic floor exercise program on incontinence and sexual dysfunction in multiple sclerosis patients Altunan et al., IJUN, (2021) 53:1059.
    McNicholas DP; Floyd MS; Mann KR; Khadr RN; Young CA
    Int Urol Nephrol; 2021 Nov; 53(11):2297-2298. PubMed ID: 34292491
    [No Abstract]   [Full Text] [Related]  

  • 12. Letter to Editor Regarding the Article Entitled "Treatment Effects for Dysphagia in Adults with Multiple Sclerosis: A Systematic Review".
    Zainaee S; Mahdipour R; Ghaemi H
    Dysphagia; 2021 Dec; 36(6):1114-1115. PubMed ID: 33237365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost-effectiveness of bisphosphonates in metastatic breast cancer: letter to the editor in response to Botteman et al. 2006.
    Souberbielle B; Williams R; McCloskey E
    Ann Oncol; 2007 Feb; 18(2):393. PubMed ID: 17043093
    [No Abstract]   [Full Text] [Related]  

  • 14. Urinary catheter monitoring of intra-abdominal pressure after major abdominal surgery, a cost-benefit analysis.
    Ney JP; Moll V; Kimball EJ
    J Med Econ; 2022; 25(1):412-420. PubMed ID: 35282753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Important Considerations When Determining the Cost-effectiveness of Viscosupplements in the Treatment of Knee Osteoarthritis: Letter to the Editor regarding Rosen, J., Sancheti, P., Fierlinger, A. et al. Adv Ther (2016) 33: 998. doi:10.1007/s12325-016-0331-8.
    Daley W
    Adv Ther; 2017 Jan; 33(12):2269-2272. PubMed ID: 27778298
    [No Abstract]   [Full Text] [Related]  

  • 16. Response to Feemster KA et al. letter to the editor on Cost-effectiveness analysis for PCV13 in adults 60 years and over with underlying medical conditions which put them at an elevated risk of pneumococcal disease in Japan.
    Igarashi A; Hirose E; Kobayashi Y; Yonemoto N; Lee B
    Expert Rev Vaccines; 2022 May; 21(5):591-592. PubMed ID: 35104176
    [No Abstract]   [Full Text] [Related]  

  • 17. Letter to the Editor concerning "Cost-effectiveness of conservative versus surgical treatment strategies of lumbar spinal stenosis in the Swiss setting: analysis of the prospective multicenter Lumbar Stenosis Outcome Study (LSOS)" by A. Aichmair et al. (Eur Spine J; 2016. doi:10.1007/s00586-016-4937-y).
    Avellanal M
    Eur Spine J; 2017 Apr; 26(4):1316-1317. PubMed ID: 28204926
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost-utility analysis of alemtuzumab in comparison with interferon beta, fingolimod, and natalizumab treatment for relapsing-remitting multiple sclerosis in Austria.
    Walter E; Berger T; Bajer-Kornek B; Deisenhammer F
    J Med Econ; 2019 Mar; 22(3):226-237. PubMed ID: 30522373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reply to the Letter to the Editor of M. Avellanal concerning: "Cost-effectiveness of conservative versus surgical treatment strategies of lumbar spinal stenosis in the Swiss setting: analysis of the prospective multicenter Lumbar Stenosis Outcome Study (LSOS)" by A. Aichmair et al. (Eur Spine J; 2016. doi:10.1007/s00586-016-4937-y).
    Aichmair A; Farshad M
    Eur Spine J; 2017 Apr; 26(4):1318-1319. PubMed ID: 28190205
    [No Abstract]   [Full Text] [Related]  

  • 20. Letter to the Editor: comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis.
    Parekh K; Watkins C
    J Comp Eff Res; 2021 Dec; 10(17):1265-1266. PubMed ID: 34608807
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.